Erratum to: Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas: ITF2357 activity against c-Myc+ B-cell lymphomas (International Journal of Cancer, (2014), 135, 9, (2034-2045), 10.1002/ijc.28852);Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas

International Journal of Cancer

Volumn 135, Issue 9, 2014, Pages 2034-2045

  Zappasodi, Roberta ^a,e   Cavanè, Alessandra ^a   Iorio, Marilena V ^a   Tortoreto, Monica ^a   Guarnotta, Carla ^b   Ruggiero, Giusi ^a   Piovan, Claudia ^a   Magni, Michele ^a   Zaffaroni, Nadia ^a   Tagliabue, Elda ^a   Croce, Carlo M ^c   Zunino, Franco ^a   Gianni, Alessandro M ^a,d   Di Nicola, Massimo ^a,e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e NONE   (Italy)

Author keywords

c Myc; histone deacetylase inhibitors; microRNA; non Hodgkin lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; GIVINOSTAT; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4G; LET 7A; MESSENGER RNA; MICRORNA; MICRORNA 26A; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B-CELL LYMPHOMA CELL LINE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DOWN REGULATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REMISSION; SCID MOUSE; TUMOR XENOGRAFT;

C-MYC; HISTONE DEACETYLASE INHIBITORS; MICRORNA; NON-HODGKIN LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; LYMPHOMA, B-CELL; MICE; MICE, SCID; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84906240240     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30890     Document Type: Erratum

References (50)

1. Slack GW, Gascoyne RD,. MYC and aggressive B-cell lymphomas. Adv Anat Pathol 2011; 18: 219-28.
2. Chng WJ, Huang GF, Chung TH, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-35.
3. Boxer LM, Dang CV,. Translocations involving c-myc and c-myc function. Oncogene 2001; 20: 5595-610.
4. Di Nicola M, Carlo-Stella C, Mariotti J, et al. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol 2004; 126: 815-20.
5. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet 2012; 379: 1234-44.
6. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-5.
7. Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012; 119: 4619-24.
8. Hartmann E, Fernandez V, Moreno V, et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008; 26: 4966-72.
9. Harris AW, Pinkert CA, Crawford M, et al. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353-71.
10. Felsher DW, Bishop JM,. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199-207.
11. Li Z, Van Calcar S, Qu C, et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 2003; 100: 8164-9.
12. Zippo A, De Robertis A, Serafini R, Oliviero S,. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932-44.
13. Kurland JF, Tansey WP,. Myc-mediated transcriptional repression by recruitment of histone deacetylase. Cancer Res 2008; 68: 3624-9.
14. Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer Cell 2012; 22: 506-23.
15. Zhang X, Chen X, Lin J, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012; 31: 3002-8.
16. Zhao X, Lwin T, Zhang X, et al. Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity. Leukemia 2013; 27: 2341-50.
17. Bahram F, von der Lehr N, Cetinkaya C, et al. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95: 2104-10.
18. Pelengaris S, Khan M, Evan G,. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-76.
19. Gomez-Curet I, Perkins RS, Bennett R, et al. c-Myc inhibition negatively impacts lymphoma growth. J Pediatr Surg 2006; 41: 207-11; discussion 11.
20. Seo SK, Jin HO, Woo SH, et al. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol 2011; 6: 1313-9.
21. Kretzner L, Scuto A, Dino PM, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 2011; 71: 3912-20.
22. Sander S, Bullinger L,. Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle 2009; 8: 556-9.
23. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67: 9762-70.
24. Kim HH, Kuwano Y, Srikantan S, et al. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev 2009; 23: 1743-8.
25. Lin CJ, Cencic R, Mills JR, et al. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res 2008; 68: 5326-34.
26. Zappasodi R, Pupa SM, Ghedini GC, et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 2010; 70: 9062-72.
27. Zappasodi R, Bongarzone I, Ghedini GC, et al. Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood 2011; 118: 4421-30.
28. Lewis TS, McCormick RS, Stone IJ, et al. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 2011; 25: 1007-16.
29. Barbetti V, Gozzini A, Rovida E, et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008; 27: 1767-78.
30. Sonenberg N, Hinnebusch AG,. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136: 731-45.
31. Hammerman PS, Fox CJ, Birnbaum MJ, et al. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105: 4477-83.
32. Nawijn MC, Alendar A, Berns A,. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011; 11: 23-34.
33. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011; 108: 16669-74.
34. Kessler JD, Kahle KT, Sun T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012; 335: 348-53.
35. Zhu C, Chen Q, Xie Z, et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med 2011; 89: 279-89.
36. Maroney PA, Yu Y, Fisher J, et al. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat Struct Mol Biol 2006; 13: 1102-7.
37. Kong YW, Cannell IG, de Moor CH, et al. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci USA 2008; 105: 8866-71.
38. Sander S, Bullinger L, Klapproth K, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-12.
39. Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-92.
40. Sampath D, Liu C, Vasan K, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119: 1162-72.
41. Schatz JH, Oricchio E, Wolfe AL, et al. Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 2011; 208.
42. Zhang Y, Wang Z, Li X, et al. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008; 27: 4809-19.
43. Kumar A, Marques M, Carrera AC,. Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry. Mol Cell Biol 2006; 26: 9116-25.
44. Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012; 22: 167-79.
45. Lin CJ, Nasr Z, Premsrirut PK, et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. Cell Rep 2012; 1: 325-33.
46. Gomez-Abad C, Pisonero H, Blanco-Aparicio C, et al. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 2011; 118: 5517-27.
47. Hsi ED, Jung SH, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008; 49: 2081-90.
48. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-20.
49. Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008; 112: 1886-93.
50. Furlan A, Monzani V, Reznikov LL, et al. Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med 2011; 17: 353-62.